
Overview
Nanoexpo is a biotech start-up that provides R&D services in bioengineering, specifically focusing on the design and manufacturing of enveloped and non-enveloped virus-like particles (VLPs). The company also offers services for producing polyclonal antibodies and designing antigens for vaccine development and diagnostic tests using various cell-based platforms. Additionally, they work with biological nanostructures capable of carrying genetic material.
Financials
Revenue history (in k)
From the notes
| Loans and borrowings | $41,412 |
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 254 days for 2024).
- 202504/08/2026
- 202426/03/2026
- 202318/07/2024
- 202213/07/2023
- 202106/10/2022
- 202008/04/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Biotechnology research and development services
- Biological nanostructure design
- Virus-like particle production
- Antigen design
- Polyclonal antibody production
- Laboratory services
Websites
- nanoexpo.euNaNoEXPO – terapie nowej generacjiGoogle AnalyticsGoogle Tag ManagerApache
Authorized Representatives
Manner of representation
In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Beata Marta Gromadzka age 47 | 51 | $688.82 | 51% |
| 40 | $540.25 | 40% | |
Others | 9 | $121.56 | 9% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Hybridovax sp. z o.o. | 540.25 USD | 40% |
Bank accounts
Registered as a VAT taxpayer on 2021-11-27.
70 1050 1764 1000 0090 8106 1195
58 1050 1764 1000 0024 6992 3979
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 28, 2025 | Aid for research and development projects: industrial research | $80,175$80,175 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Dec 29, 2021 | Aid for research and development projects: industrial research | $171.1K$171,118 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Dec 29, 2021 | Aid for research and development projects: experimental development | $141.7K$141,736 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-03-01 | Application of modern biotechnological and bioinformatic techniques to develop virus-like particles for diagnostic and therapeutic purposes. | $1.2M$1,162,487 | European Funds for Pomerania 2021-2027 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Bioactive-Tech sp. z o.o. | $228,068.15 | bioactivetech.pl | ||
| Phage Consultants sp. z o.o. | $193,130.82 | phageconsultants.com | ||
| Biotts S.A. | $159,262.71 | biotts.com | ||
| Cofactor sp. z o.o. | $136,474.66 | cofactor.pl | ||
| Awtm sp. z o.o. | $123,062.45 | awtm.pl | ||
| Rebread Alcohol & Beverages sp. z o.o. | $103,277.29 | rebread.com | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Fly-Gen sp. z o.o. | $45,325.87 | fly-gen.pl |
FAQ
Last updated: 2026-08-06